close
MENU
Investment
4 mins to read

AFT’s core Australian business under-appreciated, analysts say

Forsyth Barr rates the Kiwi pharma as an outperform stock.

AFT Pharmaceuticals CEO Dr Hartley Atkinson.

The market has underappreciated Kiwi drug manufacturer AFT Pharmaceuticals’s core Australia business, says Forsyth Barr in a glowing note after expanding its coverage of the stock.

The NZX and ASX-listed company’s share price has been languishing this year, down 20% on a year ago but Forsyth

Want to read more? It's easy.

Choose your best value subscription option

Student

Exclusive offer for uni students studying at a New Zealand university (valued at $499).
Individual
Group membership
NBR Marketplace

Yearly Premium Online Subscription

NZ$499.00 / yearly

Monthly Premium Online Subscription

NZ$44.95 / monthly

Smartphone Only Subscription

NZ$24.95 / monthly

Premium Group Membership 10 Users

NZ$350+GST / monthly

$35 per user - Pay by monthly credit card debit

Premium Group Membership 20 Users

NZ$600+GST / monthly

$30 per user - Pay by monthly credit card debit

Premium Group Membership 50 Users

NZ$1250+GST / monthly

$25 per user - Pay by monthly credit card debit

Premium Group Membership 100 Users

NZ$1875+GST / monthly

$18.75 per user - Pay by monthly credit card debit

Yearly Premium Online Subscription + NBR Marketplace

NZ$499.00 / yearly

Already have an account? Login
Fiona Rotherham Wed, 12 Oct 2022
Contact the Writer: fiona@nbr.co.nz
News tip? Question? Typo? Let us know: editor@nbr.co.nz
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Company profile
Powered by: nzx logo
Change:
Price
Previous Close
Turnover
Movement
Volume
Avg Daily Volume
Daily High
Daily Low
52 Week High
52 Week Low
AFT’s core Australian business under-appreciated, analysts say
Investment,
96135
true